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ABSTRACT
Introduction The treatment standard for high-risk upper
urinary tract urothelial carcinoma (UUTUC) is radical
nephroureterectomy. However, some patients may be unfit
or unwilling, and in such patients the available alternatives
are suboptimal. Therapies targeting the programmed death
(PD) pathway have shown promise in urothelial carcinom
(UC). We designed the current study to determine the safety
and efficacy of administering MK-3475 (a monoclonal
antibody targeting interaction between PD-1 and its ligand) in
combination with bacillus Calmette-Guerin (BCG) in high-risk
non-muscle invasive UUTUC patients.
Methods This represents a single-centre phase-II efficacy
study of MK-3475 therapy in combination with BCG for
subjects, 18 years of age or older, with pathologically
documented non-muscle invasive high-risk UUTUC unfit
or unwilling to be treated with radical nephroureterectomy.
Twenty subjects will be enrolled; patients will receive
treatment with 200 mg of MK-3475 every 21 days, starting
2 weeks from the initial endoscopic resection and continuing
for 6 weeks after the final dose of BCG. The primary objective
is to determine the safety and efficacy of administering MK3475 at a fixed dose of 200 mg every 3 weeks in conjunction
with intrapelvic BCG. Secondary objectives include 19 week
and the 3, 12 and 24-month post-treatment completion
complete response and progression-free rate assessments.
Ethics and dissemination The study has been approved
by the Institutional Review Board of the Henry Ford
Hospital. The results of this study will be published in
a peer-reviewed journal and presented at a scientific
conference.
Trial registration number NCT03345134

Strengths and limitations of this study
►► One of the first clinical trials to assess the safety

and efficacy of programmed death (PD)-1 inhibitors
in combination with bacillus Calmette-Guerin (BCG)
for subjects with non-muscle invasive high-risk upper urinary tract urothelial carcinoma (UUTUC) after
endoscopic ablation.
►► Study provides extensive follow-up and multiple objective measures assessing the safety and efficacy
of PD-1 inhibitors.
►► This study is non-randomised and unblinded with
long-term enrolment and frequent clinical obligations may result in failure in the retention of subjects.
►► Small sample size given rarity of disease and patient
eligibility criteria.
►► In the present study, accurate staging of non-muscle
invasive UUTUC is solely dependent on endoscopic
biopsy, which has been previously shown to result in
understaging when compared with final pathology.

However, several patients with this disease
have multiple comorbidities and are unfit for
surgery, while others are unwilling to have such
a radical surgery performed, especially when
faced with a real risk of dialysis in the setting of
bilateral tumours, tumour in a solitary kidney
(congenital or after nephrectomy for a prior
malignancy) or baseline renal insufficiency.
Endoscopic treatment is an alternative to
radical nephroureterectomy. Patients that are
candidates for endoscopic management of
Introduction
Upper urinary tract urothelial carcinomas high-risk disease have been extensively studied,
(UUTUCs) account for approximately 5% of and the eligibility criteria include lesions that
urothelial malignancies and 5%–10% of renal are papillary and superficial, completely visualcancers.1 The treatment standard for high- ised and <2 cm in diameter with no computed
risk UUTUC is radical nephroureterectomy. tomographic evidence of parenchymal
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invasion.2 Further, in efforts to decrease recurrence, adjuvant bacillus Calmette-Guerin (BCG) treatment has been
used.3–5 Unfortunately, more than 50% of patients recur by
5 years.2 3 Hence, identification of new agents active in this
disease is warranted.
The blockade of immune checkpoint pathway involving
programmed death 1 (PD-1) receptor and its ligands,
CD274 (PD-L1) and CD273 (PD-L2), has been recently
shown to be effective in cancer therapy including for UC.6 7
Furthermore, the treatment effect of PD-1 blockade may
be exaggerated in UUTUC due the high prevalence of
mismatch repair defects in these tumours.8 9 We hypothesise
that a combination of pembrolizumab and BCG following
endoscopic treatment of high-risk UUTUC may be effective
in improving outcomes of UUTUC after endoscopic treatment in patients unfit or unwilling to be treated with radical
nephroureterectomy. The aim of this study is to determine
the safety and response of administering MK-3475 (a monoclonal antibody designed to block the interaction between
PD-1 and its ligand) in conjunction with BCG treatment
in high-risk non-muscle invasive UUTUC patients. In this
paper, we report the treatment protocol for the study.
Methods and analysis
Rationale
PD-1 is an inhibitory cell-surface receptor that can be stimulated to be expressed on T cells, B cells, natural killer
T cells, monocytes and dendritic cells (DCs).10 PDL-1 is
widely expressed by hematopoietic, non-hematopoietic and
tumour cells, whereas PDL-2 is expressed mainly by DCs and
macrophages.10 11 Higher expression of PDL-1 in cancers
is associated with poor survival as tumours can evade the
immune system by stimulating PD-1.12–14 Clinical trials with
antibodies targeting PD-1 and PDL-1 have shown promising
results in advanced cancers. In a study presented at the
2014 annual meeting of the American Society of Clinical
Oncology, humanised monoclonal IgG4 anti-PD-1 antibody
MK-3475 was administered to a non-randomised Cohort
of 411 ipilimumab-
naive (IPI-
N) and IPI-
treated (IPI-
T)
melanoma patients. The authors observed that among
the 365 patients with measurable disease at baseline, an
overall response rate by response evaluation criteria in solid
tumors (RECIST) criteria was 40% (95% CI 32% to 48%)
in IPI-N and 28% (95% CI 22% to 35%) in IPI-T patients,
and that the responses were durable. Median progression
free survival by RECIST criteria was 24 weeks in IPI-N and
23 weeks in IPI-T patients and median overall survival (OS)
was not reached, with 1 year OS of 71% in all patients. The
authors then concluded that MK-3475 showed durable
responses and a manageable safety profile across dose and
schedules in IPI-N and IPI-T melanoma patients (http://
meetinglibrary.asco.org/content/133842-144).
PDL-1 expression, a marker for response to anti-PD-1
agents, is observed in 7% of pTa, 16% of pT1 and 45%
of carcinoma in situ (CIS) urothelial tumours.15 PDL-1
expression in these tumours is also associated with high-
grade disease. In addition, PDL-1 expression is found to
2

be extremely abundant in the BCG-induced transitional
epithelium granulomata in patients failing BCG treatment.15 Furthermore, as noted above, UUTUCs have aberrations in DNA mismatch repair genes that are detectable
as microsatellite instability ((MSI); in about 45%).8 This
is important because pembrolizumab has been shown
previously to have increased activity in tumours with
mismatch repair deficiency. Le et al conducted a phase-II
study to evaluate the clinical activity of pembrolizumab
in 41 patients with progressive metastatic carcinoma with
or without mismatch-repair deficiency. The authors then
found that the immune-related objective response rate and
immune-
related progression-
free survival rate were 40%
(4 of 10 patients) and 78% (7 of 9 patients), respectively,
for mismatch repair-deficient colorectal cancers and 0% (0

Figure 1 aAblation may be performed in an antegrade
or retrograde fashion. bSix weekly doses of BCG in total.
c
Patients with suspicious lesions, or positive cytology, will be
evaluated with renal pelvis biopsy under general anaesthesia.
BCG, bacillus Calmette-Guerin; UUTUC, upperurinary tract
urothelial carcinoma.
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of 18 patients) and 11% (2 of 18 patients) for mismatch
repair-proficient colorectal cancers.9 Based on these data,
a combination of pembrolizumab with BCG may be effective in preventing recurrence of UUTUC after endoscopic
treatment.
Trial blinding
This is an open-label trial; therefore, the Sponsor, investigator and subject will know the treatment administered.
Study design
This is a single centre phase-II efficacy study of MK-3475
therapy used in combination with renal pelvis infused BCG
treatment for subjects, 18 years or older, with pathologically documented high-
risk superficial UUTUC unfit or
unwilling to be treated with radical nephroureterectomy.
Subjects will have confirmation of UUTUC non-invasive
to the muscle. Approximately 30 subjects will be screened
to treat 20 eligible subjects. Subjects will be enrolled to a
single treatment group of a fixed dose of MK 3475 and BCG
(figure 1). Patients to undergo regular follow-up including
applicable labs, in addition to post-
treatment ureteroscopy with clinically indicated biopsy to assess recurrence
(figure 2).
Trial schedule
Trial schedule (figure 2) summarises the trial procedures to
be performed at each visit. It may be necessary to perform
these procedures at unscheduled time points if deemed
clinically necessary by the investigator. Furthermore, additional evaluations/testing may be deemed necessary by
the sponsor for reasons related to subject safety. In some
cases, such evaluation/testing may be potentially sensitive
in nature (eg, HIV, hepatitis C and so on), and thus local
regulations may require that additional informed consent
be obtained from the subject. In these cases, such evaluations/testing will be performed in accordance with those
regulations.
Patient selection
Subjects, who meet required inclusion and exclusion
criteria are eligible for enrolment into the study (figures 3
and 4).
Patient and public involvement
Patient and public were not involved in the design,
recruitment and conduction of the present study. Results
of the study will be disseminated to the study participants
on request. Patient advisors were not used in the conduction of this study.
Trial treatment dosage, formulation, preparation and
frequency
Bacillus Calmette-Guerin
The rationale for the use of the indicated dose of BC is
based on Food and Drug Administration (FDA) approved
and commercially provided product. Dosing for the intraluminal treatment of CIS and for the prophylaxis of recurrent
papillary tumours consists of one vial of BCG suspended in
Jamil ML, et al. BMJ Open 2019;9:e027066. doi:10.1136/bmjopen-2018-027066

50 mL preservative-free saline. The preparation of the BCG
suspension will be completed using aseptic technique and
according to FDA approved labelling and use information.
Patients may have treatment with more than one vial to
ensure treatment of all tumour sites. BCG treatment will
be administered beginning on day 1 of cycle 3 (week 7)
of MK-3475 after all procedures/assessments have been
completed as detailed on the trial flowchart. BCG treatment will be repeated every 7 days at weeks 8–12. BCG treatment may be administered up to 1 day before or after the
scheduled date (at 7 days) due to administrative reasons.
All trial treatments will be administered on an outpatient
basis and according to institutional standards. BCG dose
modification has been shown to reduce efficacy; therefore,
no dose modifications will be attempted in this trial. The
dose, frequency, route of administration and duration are
summarised in figure 5.
BCG treatment will be withheld for grade two hematuria,
grade one fever and drug-related grade four hematologic
toxicities, and all other non-haematological toxicity grade
≥3 adverse effects including laboratory abnormalities and
severe or life-threatening AEs. Treatment will be postponed
until resolution of febrile illness, urinary tract infection or
gross hematuria and adverse effect resolution to grade <1.
In the event of a grade 1 or 2 immune-related adverse event
requiring corticosteroid treatment, BCG treatment may be
delayed for up to 2 weeks with the expectation that steroid
treatment will be discontinued prior to the next BCG treatment cycle. A delay of longer than 2 weeks will permanently
discontinue the patient from BCG treatment within the
study or permanent withdrawal of the patient from the
study. The choice will be at the discretion of the treating
investigator. Steroid treatment for grade three or higher
immune mediated events will require discontinuation of
BCG treatment and/or withdrawal from the study.
MK-3475
The dose regimen of 200 mg Q3W (every 3 weeks) of
MK-3475 is planned for all urothelial cancer trials. Trial
treatment will be administered on day 1 of each cycle
after all procedures/assessments have been completed
as detailed on the trial flowchart. Trial treatment may be
administered up to 3 days before or after the scheduled
day 1 of each cycle reasons secondary to administration.
Adverse events (both non-serious and serious) associated
with pembrolizumab exposure may represent an immunologic aetiology. These adverse events may occur shortly after
the first dose or several months after the last dose of treatment. Pembrolizumab must be withheld for drug-related
toxicities and severe or life-threatening AEs. Known and
theoretical risks of MK-3475 are documented within the
original study protocol and management of said risks and
AE’s is also noted within the original study protocol.
Objectives
Primary objective
To determine safety and efficacy of administering
MK-3475 at a fixed dose of 200 mg every 3 weeks in
3
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Figure 2 aMain study screen visit: subjects who appear eligible will be consented with a main study consent allowing for all
study screening and treatment procedures. Screening visit laboratory procedures may be used for day 1 cycle 1 if completed
within 10 days of day 1 cycle 1. bDiscontinuation visit: all subjects who discontinue treatment early for any reason should
undergo all procedures listed in the flow chart for discontinuation visit. If a subject has completed all study treatment, the
subject should complete the 30-day follow-up visit procedures listed in the flow chart. cFollow-up visits should occur at
approximately 3, 6, 9, 12, 18 and 24 months from week 19 ureteroscopy. A 2-week window before and after the specified
date is allowable to meet the timelines listed. Subject will complete final set of Questionnaires at the 3-month visit. Complete
response follow-up information may be collected via medical record and document review only. However, patient contact
via phone or in person may occur if information is not available via chart review.dSubject Identification card may be given at
any time after main study informed consent has occurred and prior to treatment on day 1 cycle 1. ePrior and concomitant
medications will include any medications taken within the 28 days prior to main study consent and through the safety visit
and will include prescribed, over-the-counter and herbal/alternative remedies. fPost-study treatment anticancer therapy and
recurrence status may be collected through follow-up chart review. gTo monitor for systemicdissemination of BCG infection,
daily phone calls of days 2–4 of each cycle of BCG treatment (weeks 7–12) will occur to monitor for fever and symptoms of
systemic infection. Subjects will each be given anoral thermometer and a diary to record oral temperature twice daily (morning
and evening) and to record any symptoms they may be having.The diary will be utilised days 1–7 for each of the six BCG cycles
(weeks 7–12). hTransurethral resections: all TUBR will occur as part of SOC and as clinically indicated. For the purposes of
entry into this study, the screening window for endoscopic ablation with repeat biopsy will be within 90 days of day 1. iAdverse
events will be collected from the time of main study informed consent through 30 days post last study drug infusion/treatment.
j
Physical exam: full physical exams are required at screening and at the 30-day follow-up. All other exams may be symptom
directed. kPerformance status: ECOG performance status scale should be used. lECG, chest X-ray and pulmonary function tests
will be completed prior to day 1 cycle 1 and will only be repeated as clinically indicated. mPT/INR and aPTT will be completed
prior to all resections/possibly biopsies as standard of care. All other monitoring of PT/INR and aPTT will be completed as
clinically indicated (ie, if on Coumadin).nUreteroscopy will be performed as standard of care but will be considered measuresfor
efficacy. Biopsy will be performed as clinically indicated.oSpecimen collection/correlative studies: whole blood,serum and
urine will be collected at the time of screening consent/main study consent (only one collection at either time point) as well as
each visit through week 19 repeat ureteroscopy (12 visits). Saliva will be collected only at baseline. Tumour tissue will only be
collected at baseline and at week 19 biopsy if a biopsy is clinically indicated at the time of ureteroscopy. Specimen collection is
requested at the 3, 6, 9, 12, 18, and 24-month follow-up visits if the subject is being treated locally at the site. Tissue will only
be collected if a biopsy is clinically indicated at the time of ureteroscopy. pChest X-rays performed in the 90 days’ window prior
to the screening visit are acceptable. qCBC,CMP and correlative labs do not need to be repeated on day 1 cycle 1 if they were
completed within 10 days prior to day 1 cycle 1 during screening. aPTT, activated partial thrombin time; BCG, bacillus Calmette-
Guerin; CB, complete blood count; CMP, comprehensive metabloic panel; ECOG, Eastern Cooperative oncology Group; HCG,
Human chorionic gonadotrophin; INR, International Normalization Ratio; PT, Prothrombin time; SOC, standard of care; TURBT,
Transurethral resection of bladder tumor; TSH, Thyroid stimulating hormone; UUTUC, upperurinary tracturothelial carcinoma.
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Figure 3 aAll pathology specimens used for enrolment are required to be trad by the research site pathology laboratory.
b
Patients are to have provided tissue from an archival tissue sample or newly obtained core or excisional biopsy of a tumour
lesion. tissue must be obtained from the most recent upper urinary tract biopsy. However, in patients with small tumours or
carcinoma in situ of the upper urinary tract, and considering the difficulty of obtaining sufficient tissue for testing beyond
pathologic diagnosis, not providing this tissue is not going to exclude the patient from the study. cIf the urine test is positive
or cannot be confirmed as negative, a serum pregnancy test will be required. dSubjects of childbearing potential are those
who have not been surgically sterilised or have not been free from menses for >1 year. CIS, carcinoma in situ; ECOG, Eastern
Cooperative Oncology Group; UUTUC, upperurinary tract urothelial carcinoma.

conjunction with intrapelvic BCG in high-risk superficial
UUTUC patients, who are unfit or unwilling to be treated
with radical nephroureterectomy.

MK-3475 and intrapelvic BCG therapy for non-muscle
invasive high-risk UUTUC for patients unfit or unwilling
to be treated with radical nephroureterectomy.

Secondary objective
To determine the 19 weeks and the 3-month, 12-month
and 24-
month post-
treatment completion complete
response rate and progression-free rate with combined

Exploratory objectives
treatment
Three objectives: to examine pre- and post-
(MK-3475/BCG) renal pelvis biopsy specimens for PD-1,
L1 and CD3; to examine whole exome sequencing
PD-

Figure 4 aChest X-ray, CT urogram or MRI, and urogram are allowed to ascertain the superficial nature of the disease when
indicated, but not required. if urogram protocol is not available or contrast allergy/poor renal function precludes such imaging,
then non-contrast CT or MRI of the abdomen/pelvis within 90 days of study entry will suffice. bExceptions include basal
cell carcinoma of the skin, squamous cell carcinoma of the skin, localised prostate cancer with no recurrence after curative
surgery or radiation, or in situ cervical cancer that has undergone potentially curative therapy. lower urinary tract transitional
cell carcinoma is also allowable on study as high-risk transitional cell carcinoma is commonly multifocal, and intraluminal BCG
therapy is also used for treatment of lower urinary tract lesions in a manner similar to that of UUTUC. cUse of disease modifying
agents, corticosteroids or immunosuppressive drugs. replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency and so on) is not considered a form of systemic treatment. dThis
includes anything that may confound the results of the trial, interfere with the subject’s participation for the full duration of the
trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. eSubjects will not be
specifically tested for the study; however, subjects that are tested within 28 days of beginning study or while on study and test
positive with the PPD test before treatment should have active tuberculosis ruled out before therapy begins for their superficial
renal pelvis cancer. BCG, bacillus Calmette-Guerin; PPD, purified protein derviative; TCC, transitional cell carcinoma; TUR,
transurethral resection; UUTUC; upperurinary tract urothelial carcinoma.
Jamil ML, et al. BMJ Open 2019;9:e027066. doi:10.1136/bmjopen-2018-027066
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Figure 5 aMK-3475 dosing interval may be increased due
to toxicity as is described in the dose modification and
adverse effects section. BCG treatment may be interrupted
or delayed as per the dose modification and adverse effects
section. bBCG: one vial of TICE BCG suspended in 50 mL
preservative-free saline. BCG is to be given through a urinary
catheter into the renal pelvis either retrograde or antegrade
through a nephrostomy tube. BCG treatment will occur once
per week for 6 weeks. BCG treatment will commence on the
third cycle of treatment with MK-3475, week 7. BCG is an
FDA-approved treatment and will be supplied commercially
through the study site pharmacy. The preparation of the BCG
suspension will be completed using aseptic technique and
according to FDA-approved labelling and use information.
Patients may have treatment with more than one vial to
ensure treatment of all tumour sites. additional lesions in
patients with multi-focal disease will be treated per intuitional
standard and directed by the treating urologist. BCG, bacillus
Calmette-Guerin; FDA, Food and Drug Administration.

of subjects’ germline DNA and formalin fixed, paraffin
embedded tissue. With analysis of the correlation of mutations to treatment outcomes; analysis of blood and urine
specimens from enrollees for potential development of
blood and urine assays for determination of response to
treatment.
Adverse effects
The investigator or qualified designee will assess each
subject to evaluate for potential new or worsening AEs as
specified in the detailed trial schedule and more frequently,
if clinically indicated. Adverse experiences will be graded
and recorded throughout the study and during the
follow-up period according to NCI CTCAE V.4.0. Toxicities will be characterised in terms regarding seriousness,
causality, toxicity grading and action taken with regard to
trial treatment. AEs will be recorded from the time the
subject signs the consent through 30 days post the last study
treatment. All AEs of unknown aetiology associated with
MK-3475 exposure should be evaluated to determine if it is
possibly an event of clinical interest of a potentially immunologic aetiology (irAE).
All known and theoretical risks and adverse effects of
BCG and MK-3475 are documented within the original
study protocol for reference. Potential adverse effects and
risks are to be monitored for during each mandatory clinical visit. All of the known and theoretical risks and adverse
effects of BCG and MK-3475 are to be managed by the
investigational team and all other necessary support staff.
Management of the aforementioned risks and AEs is documented within the original study protocol.
Statistical measures and analysis
This protocol aims at assessing the activity of one treatment arm, BCG in combination with pembrolizumab
after endoscopic ablation in patients with UUTUC. We
6

would like to detect an activity which is at least 25%
greater than that of historical controls (50%) from case
series of BCG only treatment.
Sample size calculation for this protocol is based on the
work by Kahn et al16 (2012). Using a one-stage design, 20
patients will be enrolled in this study. If 14 or more patients
respond then the trial will stop. This design has 78.8% power
to determine at the end whether the experimental arm is
better than the historical control with a 1-sided type I error
rate of 0.057. This design was selected because UUTUC is a
rare disease, and we are willing to minimally sacrifice power
to reach a sample size that could be achieved within the
suggested study period and resources. Patient-related data
will be collected and transferred to an excel spreadsheet for
statistical analysis. SAS V.9.4 will be used for all data analysis.
Descriptive statistics will be computed for all study variables.
Continuous variables will be described with measures of
central tendency (mean, median) and dispersion (range,
SD). Categorical variables will be summarised as frequencies and percentages. Some examples include tumour stage
(Ta, T1, CIS), age, Eastern Oncology Cooperative Group
(ECOG) performance Scale (0, 1, 2), sex and the use of
tobacco and alcohol.
For the primary objective, the proportion of patients
with each AE will be reported along with the NCI CTCAE
grade of the AE (V.4.0). The Quality of Life Questionnaire, which includes one question with seven categorical
responses, will be described with frequencies and percentages. The American Urologic Association Symptoms Index
Questionnaire, which includes seven questions each with a
numerical score between 0 and 5 as well as a final numerical sum of all responses, will be described with measures of
central tendency and dispersion. Due to the questionnaires
being given at three time points (pretreatment, midtreatment and post-treatment), the responses may be analysed
to look for longitudinal effects over time for specific variables of interest with repeated measures analysis of variance
(ANOVA) to evaluate changes and control for individual
differences (although this would be very low power due to
n=15).
For the secondary objective, subjects will be assessed
at 19 weeks, 3 months, 12 months and 24 months post-
treatment completion for complete response. The
outcome endpoint will be complete response status at
19 weeks, 3 months, 12 months and 24 months post-
treatment to measure complete response, recorded as yes
or no and summarised as proportions and a percent.
For the exploratory objectives, Pearson or Spearman’s
rank correlation coefficient will be used to estimate
correlations between expression level change and treatment outcome, as well as the correlations between mutation presence and treatment outcome.
Ethics, confidentiality and regulatory details
The investigator and sponsor of the study will adhere to all
applicable data privacy and confidentiality laws and regulations (ie, health information portability and protection
Jamil ML, et al. BMJ Open 2019;9:e027066. doi:10.1136/bmjopen-2018-027066
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act (HIPAA)). Those applicable include institutional,
state and Federal Law. It is the responsibility of the investigator and sponsor to ensure the subject data as well as
sensitive study information is handled according to applicable guidelines and laws. Appropriate authorisation and
consent for use, disclosure or transfer of protected health
information must be obtained.
Subject names will not be recorded on the case report
form (CRF). Only the subject number and subject's
initials will be recorded, where permitted. If the subject's
name appears on any other document (eg, pathology
report), it must be obliterated on the copy of the document as appropriate. Study data stored on a computer
will be stored in accordance with local data protection
laws. The subjects will be informed that representatives of
the sponsor or its designee, IRB and regulatory authorities may inspect their medical records to verify the information collected, and that all personal information made
available for inspection will be handled in strictest confidence and in accordance with local data protection laws.
Qualified staff of the Sponsor will monitor the study
according to a pre-arranged monitoring plan. Monitoring
of the study will include:
►► Evaluation of study progress.
►► Verification of CRF accuracy and completeness.
►► Resolution of inconsistencies in study records.
►► Assurance of protocol requirements and investigator’s
obligations are fulfilled.
►► Assurance of compliance with applicable laws and
regulations.
Study monitors will periodically review all CRFs and
supporting source documentation of participating
subjects. The CRFs and supporting documentation must
remain up to date and available to the study monitor
as arranged. CRF data entry will be verified to correspond with source documentation (laboratory, imaging,
pathology reports and so on) and reviewed for completeness. Data discrepancies will be identified and reported to
the investigator and site staff.
Protocol deviations will be identified and recorded on
a deviation log.
Discussion
This open-label, single centre, phase-II, treatment trial
intends to investigate the safety and efficacy of MK-3475
in combination with endoscopic ablative surgery and
BCG. As previously mentioned, the optimal alternative
to management of patients unfit or unwilling to undergo
nephroureterectomy remains unknown. This prospective clinical trial attempts to provide a more definitive
treatment option for UUTUC. This study uses traditional
modalities in the form of endoscopic ablation in conjunction with newly available immunotherapeutic agents.
Technical advancement in endoscopic ablative surgical
treatment has allowed urological surgeons to provide a
less invasive option in the treatment of UUTUC. With the
development of progressively smaller and more durable
Jamil ML, et al. BMJ Open 2019;9:e027066. doi:10.1136/bmjopen-2018-027066

rigid and flexible ureteroscopes, retrograde endoscopic
procedures have become more practical and effective,
furthered by the use of different lasers (Ho:YAG and
neodymium:YAG [Nd:YAG]). Ho:YAG laser can evaporate, coagulate and resect tumours. These can be used
safely since its radiation affects only surface (<0.4 mm).3
The combination of BCG therapy has been shown to
decrease recurrence, yet despite its efficacy, recurrence
remains relatively high.
The design of the present study will allow the researchers
to discern the safety and efficacy of MK-3475 and BCG as a
viable option for high-risk superficial UUTUC. It has been
well documented that although radical nephroureterectomy provides definitive cancer control in UUTUC, the
associated morbidity and mortality continues to remain
high. A non-
surgical option following BCG-
failure is
desirable. Various other studies have demonstrated
promising results in regards to efficacy of agents such as
MK-3475 and its presumed that this trend will continue
with increased investigation and utilisation. If the intravesicular combination of MK-3475 and BCG is to yield
promising results, it would provide patients with an alternative to nephroureterectomy and potentially change the
standard of care.
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